Targeted therapies in the management of advanced medullary thyroid cancer
The Oncologist · 06.08.2026 · 31 (9)
DOI: 10.1093/oncolo/oyag300 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 29.07.2026. Verfasst von Hameeda Arif Arain und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast and Endocrine Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, United States. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma, Neuroendocrine, Molecular Targeted Therapy, Protein Kinase Inhibitors. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Institutional Research Training Grant, Ruth L. Kirschstein National Research Service Award.
Abstract (Originalsprache)
Background
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that contributes disproportionately to thyroid cancer–related mortality. Historically, systemic treatment options for advanced MTC were limited due to poor responsiveness to radioactive iodine and conventional chemotherapy. The development of targeted therapies has significantly transformed disease management.
Methods
This narrative review summarizes current evidence on targeted therapies for advanced MTC, including multikinase inhibitors (MKIs), selective RET inhibitors, and emerging treatment strategies. Literature on efficacy, safety, resistance mechanisms, and novel therapeutic approaches was evaluated.
Results
First-generation MKIs, including vandetanib and cabozantinib, demonstrated clinical benefit by targeting RET and angiogenic pathways, though off-target toxicities limited tolerability. More recently, selective RET inhibitors, such as selpercatinib and pralsetinib, have shown high response rates and improved safety profiles, establishing them as preferred first-line therapies for RET-mutant MTC. However, pralsetinib’s recent market withdrawal due to regulatory challenges highlights the need for additional options. Emerging therapies, including BOS172738, SY-5007, and peptide receptor radionuclide therapy, show promising early results. Resistance mechanisms, including gatekeeper and solvent front mutations, remain a challenge. Advances in clinical biomarkers and novel approaches, such as CAR-T cell therapy, may further support personalized treatment.
Conclusion
Targeted therapies have reshaped the management of advanced MTC, with selective RET inhibitors offering improved efficacy and tolerability. Continued research is essential to overcome resistance, expand therapeutic options, and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Breast and Endocrine Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
- Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
ORCID-Profile: Hameeda Arif Arain, Herbert Chen
Förderung
- NCI NIH HHS
- Institutional Research Training Grant
- Ruth L. Kirschstein National Research Service Award
- University of Alabama Medical Center
- NIH HHS
- National Institutes of Health
Zitieren
APA
Arain, H. A., Izhar, A., Caretti, R., Chen, H., & Vodopivec, D. M. (2026). Targeted therapies in the management of advanced medullary thyroid cancer. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag300
Vancouver
Arain HA, Izhar A, Caretti R, Chen H, Vodopivec DM. Targeted therapies in the management of advanced medullary thyroid cancer. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag300
BibTeX
@article{Arain2026,
author = {Arain, Hameeda Arif and Izhar, Azeem and Caretti, Rachael and Chen, Herbert and Vodopivec, Danica M},
title = {Targeted therapies in the management of advanced medullary thyroid cancer},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {9},
doi = {10.1093/oncolo/oyag300}
}
EUVIMED